Gapping up
In reaction to strong earnings/guidance: TNXP +17.6%, AEO +15.5%, PERY +9.4%, ROX +8.4%, WMT +8%, URBN +7.8%, ZIOP +6.4%, CRM +6.1%, CSCO +4.8%, SQM +2.3%, SQM +2.3%, DKS +2.1%, HQCL +2%, FTI +1.4%, EXP +0.5%
M&A news: CHD +8.8% (report that Reckitt (RBGLY) might bid for CHD), MON +7.6% (confirms receipt of non-binding proposal from Bayer (BAYRY)), FTI +1.2% (FMC Tech and Technip (TKPPY) to merge in all-stock transaction; combined company would have an equity value of $13 bln)
Select EU financial related names showing strength: RBS +2.9%, CS +2.3%, HSBC +2%
Other news: RPRX +23.3% (reports 'positive' clinical data for Oral Proellex ), BIND +15.7% (reaches agreement in relation to its recent Chapter 11 filing for the use of cash collateral through July 8), GEVO +15% (enters into an agreement with Clariant), TNXP +14.5% (announces topline results of the Phase 2 dose-finding clinical study of TNX-102 SL in military-related PTSD), CPXX +10.7% (granted breakthrough therapy designation to Vyxeos), ZIOP +6.4% (to present interim results from its ongoing Phase 1, multi-center dose-escalation study of the gene therapy candidate Ad-RTS-hIL-12 + orally-administered veledimex in patients with recurrent or progressive glioblastoma at ASCO), ARRY +5.4% (to present present additional data on its late-stage candidates binimetinib and encorafenib in NRAS-mutant melanoma and BRAF-mutant colorectal cancer at ASCO), GALE +3.4% (to present primary analysis from the Company's GALE-301 Phase 1/2a clinical trial at ASCO), ARIA +2.7% (to present clinical data on brigatinib at ASCO), DB +1.9% (rovides 2020 financial objectives; Fitschen will step down as Co-Chairman of the Management Board of Deutsche Bank), POT +1.8% (in symp with MON), COST +1.1% (in sympathy with WMT)
In reaction to strong earnings/guidance: TNXP +17.6%, AEO +15.5%, PERY +9.4%, ROX +8.4%, WMT +8%, URBN +7.8%, ZIOP +6.4%, CRM +6.1%, CSCO +4.8%, SQM +2.3%, SQM +2.3%, DKS +2.1%, HQCL +2%, FTI +1.4%, EXP +0.5%
M&A news: CHD +8.8% (report that Reckitt (RBGLY) might bid for CHD), MON +7.6% (confirms receipt of non-binding proposal from Bayer (BAYRY)), FTI +1.2% (FMC Tech and Technip (TKPPY) to merge in all-stock transaction; combined company would have an equity value of $13 bln)
Select EU financial related names showing strength: RBS +2.9%, CS +2.3%, HSBC +2%
Other news: RPRX +23.3% (reports 'positive' clinical data for Oral Proellex ), BIND +15.7% (reaches agreement in relation to its recent Chapter 11 filing for the use of cash collateral through July 8), GEVO +15% (enters into an agreement with Clariant), TNXP +14.5% (announces topline results of the Phase 2 dose-finding clinical study of TNX-102 SL in military-related PTSD), CPXX +10.7% (granted breakthrough therapy designation to Vyxeos), ZIOP +6.4% (to present interim results from its ongoing Phase 1, multi-center dose-escalation study of the gene therapy candidate Ad-RTS-hIL-12 + orally-administered veledimex in patients with recurrent or progressive glioblastoma at ASCO), ARRY +5.4% (to present present additional data on its late-stage candidates binimetinib and encorafenib in NRAS-mutant melanoma and BRAF-mutant colorectal cancer at ASCO), GALE +3.4% (to present primary analysis from the Company's GALE-301 Phase 1/2a clinical trial at ASCO), ARIA +2.7% (to present clinical data on brigatinib at ASCO), DB +1.9% (rovides 2020 financial objectives; Fitschen will step down as Co-Chairman of the Management Board of Deutsche Bank), POT +1.8% (in symp with MON), COST +1.1% (in sympathy with WMT)